TrialThoracic cancer2022

Two-year efficacy of SNK01 plus pembrolizumab for non-small cell lung cancer: Expanded observations from a phase I/IIa randomized controlled trial.

Hyung Jun Park et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.